Search Results

Weilan Stellar Completes China's First Stellarator Magnet Cryogenic Comprehensive Test Platform in Three Months, First Round of Magnet Testing Launched

Weilan Stellar recently completed the construction of China's first stellarator magnet cryogenic comprehensive test platform, and the first round of magnet testing has been launched. Qiu Lilong, a review expert for the cryogenic system, stated that from independent design and system integration to domestically sourced supporting equipment, Weilan Stellar took only three and a half months to integrate vacuum, cryogenics, power supply, measurement, and protection into a comprehensive test platform. The test platform fully demonstrates the team's outstanding capabilities in scientific research, engineering, and project management. As the foundation for stable operation of a stellarator, the cryogenic system's vacuum level, sealing performance, and cooling capacity are all crucial. Unlike conventional paced R&D models, Weilan Stellar has always adhered to a pragmatic,...

2026-09-23

ZAP-X Gyroscopic Stereotactic Radiosurgery Platform Makes Its Australian Debut, Expanding Precision Non-Invasive Brain Radiotherapy

ZAP Surgical, the global leader in non-invasive robotic brain surgery, recently announced that GenesisCare will become the first cancer care provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery platform. Installation of the device is scheduled to begin this month at the GenesisCare center located at St Vincent's Hospital Sydney in New South Wales, with the first patients expected to receive treatment before the end of this year. The introduction of the ZAP-X platform will significantly enhance GenesisCare's neuro-oncology diagnostic and treatment capabilities in Sydney, providing it with dedicated stereotactic radiosurgery (SRS) services. Prior to this, patients receiving S...

2026-09-17

Nusano Selected for U.S. Nuclear Energy Launch Platform Program to Advance Advanced Nuclear Fuel Production Line

Nusano, Inc., a physics company based in West Valley City, Utah, that has made breakthroughs in radioisotope and nuclear fuel production, has been selected by the U.S. Nuclear Reactor Innovation Center (NRIC) and the U.S. Department of Energy (DOE) to participate in the development of a HALEU (high-assay low-enriched uranium) nuclear fuel production line as part of the Nuclear Energy Launch Platform program. The program is a federal government initiative aimed at accelerating innovative nuclear technologies from concept to commercial deployment. Through this program, Nusano will receive authorization process support from the U.S. Department of Energy, expertise from national laboratories, infrastructure, technical resources, and project support, thereby accelerating the development of advanced nuclear technologies...

2026-09-15

Denmark's Region East Denmark to expand Sectra One imaging platform, unifying regional nuclear medicine and other medical imaging services

Swedish medical imaging IT and cybersecurity company Sectra has recently signed a contract to expand the application of its Sectra One enterprise imaging solution from hospitals in Denmark's Capital Region to the entire Region East Denmark. Region East Denmark was formed by merging the Capital Region and Region Zealand, and this expansion aims to promote unified operation of imaging services across hospitals in the entire region. Under the contract, Sectra One will be delivered as a fully managed cloud service, covering all hospitals in Region East Denmark for the review and storage of radiology medical images, including breast imaging, nuclear medicine, and clinical physiology. Hospitals in Region Zealand will migrate to the system currently in use in the Capital Region,...

2026-09-11

Australia's First ZAP-X Gyroscopic Radiosurgery Platform to Be Installed at St Vincent's Hospital Sydney

ZAP Surgical Systems has announced that GenesisCare will become the first cancer treatment provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery® platform. The device is expected to be installed this month at GenesisCare's center at St Vincent's Hospital in Sydney, New South Wales, with the first patients anticipated to begin treatment before the end of the year. The deployment of the ZAP-X platform will enhance GenesisCare's neuro-oncology treatment capabilities in Sydney, enabling it to deliver dedicated stereotactic radiosurgery (SRS). Previously, SRS patients were primarily treated using cobalt-60 systems and multi-purpose radiotherapy linear accelerators. The ZAP-X, in contrast, is a dedicated platform designed for non-inv...

2026-09-09

Russia's EVRAZ Plans to Develop High-Performance Railway Rails Using SKIF Synchrotron Radiation Platform

Russian railway infrastructure component manufacturer EVRAZ PJSC plans to cooperate with the SKIF Collective Use Center to develop new alloys and high-performance rails using synchrotron radiation experimental capabilities, aiming to improve the mechanical properties and operational reliability of rails. At a roundtable discussion on "Development of New Structural and Tool Materials and Mechanical Engineering Technologies Using Synchrotron Radiation" held during the Technoprom 2026 forum, participating experts discussed the application prospects of the SKIF Collective Use Center in the development of high-quality rolled metal products. EVRAZ stated that Russia's railway operating environment is complex, with long line distances, numerous mountain routes, prominent low-temperature conditions, coupled with growing freight volumes, placing higher demands on steel materials...

2026-09-07

Canada's Devonian Integrates HPLC-MS, NMR, and Cell-Based Potency Assays into Thykamine Quality Control Platform

Devonian Health Group Inc., a Canadian clinical-stage biopharmaceutical company, recently announced that it has completed independent validation of key analytical methods and biological quality control technologies and integrated them into the extraction and production process of Thykamine, the company's lead active pharmaceutical botanical candidate. According to the company, its quality control program includes validated high-performance liquid chromatography-mass spectrometry (HPLC-MS) chemical fingerprinting, nuclear magnetic resonance (NMR) spectroscopy, and cell-based biological potency assays based on the U937 human cell line. The relevant cell-based assays use macrophage inflammatory protein-1β (MIP-1β) as a biomarker of Thykamine's anti-inflammatory activity...

2026-09-02

Rock Fusion AI Platform Streamlines the Entire Stellarator Design Workflow

Recently, the AI agent collaboration platform for stellarator design independently developed by Rock Fusion has achieved full coverage of the entire design workflow, encompassing key stages such as zero-dimensional parameter design, plasma configuration optimization and performance analysis, as well as coil engineering feasibility assessment. The company stated that the platform can search over a thousand initial configurations and hundreds of thousands of coil schemes, reducing the typical design iteration cycle from several weeks to several days. Rock Fusion stellarator concept image. Leveraging this platform, Rock Fusion has completed the full-machine physics design of a medium-sized superconducting stellarator with a major radius of 2 meters and a central magnetic field of 3 tesla. Design work for the company's other devices under development is also being advanced on the same platform. Stellarators rely on external three-dimensional coils to directly generate helical magnetic fields, eliminating the need to sustain magnetic confinement through plasma current. This mechanism inherently reduces the risk of major disruptions faced by tokamaks and offers the potential for long-pulse steady-state operation. In 2025, Germany's Wendelstein 7-X (W7-X) stellarator achieved significant progress in the "triple product" metric during long-duration discharges, drawing greater attention to the stellarator route.

2026-09-02

Multiple Units at Tianwan Nuclear Power Plant Go Live with Self-Developed EPM System

On August 31, the EPM system, a production management platform independently developed by China National Nuclear Power (CNNP), was officially launched at Units 3, 4, 7, and 8 of Tianwan Nuclear Power Plant. This launch marks a new stage of standardized management and control for Jiangsu Nuclear Power's production management, and also provides a practical example from Tianwan Nuclear Power Plant for CNNP's digital transformation. The EPM system is a new-generation nuclear power plant production management system independently developed by CNNP with fully independent intellectual property rights. Designed to meet the operational needs of nuclear power plant field operations, the system integrates business processes such as planning, operations, maintenance, equipment, and safety permits, unifies plant-wide work execution standards, and achieves closed-loop control across the entire production management chain. The system covers...

2026-09-01

China's First Enterprise-Level Synchrotron Radiation Technology Application Research Platform Inaugurated in Shanghai

The Sinopec Shanghai Synchrotron Radiation Facility Energy and Chemical Science Laboratory, invested by Sinopec and jointly built with the Shanghai Advanced Research Institute of the Chinese Academy of Sciences, and based on the Shanghai Synchrotron Radiation Facility (SSRF) major scientific infrastructure, was recently inaugurated in Shanghai Zhangjiang Science City. This laboratory is the first enterprise-level synchrotron radiation technology application research platform in China. According to reports, the laboratory consists of three beamline stations and auxiliary laboratories, and will provide technical support and services for basic scientific research conducted by Sinopec and public users, with a focus on oil and gas exploration and development, petroleum refining and chemical engineering, and new energy and new materials. Once the platform is completed, it will help enhance the enterprise's capabilities in forward-looking and fundamental research, and provide scientific research support for cultivating new quality productive forces in China's energy and chemical industry.

2026-08-29

U.S. SUPC Completes Independent Engineering Assessment of Seawater Uranium Extraction Platform

SuperCritical Materials Corp. (SUPC) of the United States announced on August 26 that an independent engineering assessment conducted by Kellogg Brown & Root (KBR) has been completed. The assessment focused on the deployment architecture, offshore operation scheme, uranium recovery process, commercialization pathway, and key engineering conditions required for future large-scale deployment of SUPC's seawater uranium extraction platform. According to the assessment, SUPC's conceptual production plan proposes the use of approximately 10,000 tons of adsorbent, operating on a continuous 21-day deployment cycle, to supply adsorbent for a uranium processing facility with an annual production capacity of 1.85 million pounds of triuranium octoxide (U3O8)...

2026-08-28

U.S. SuperCritical Materials Corp. Completes Independent Engineering Assessment of Seawater Uranium Extraction Platform

SuperCritical Materials Corp. announced on August 26 that Kellogg Brown & Root (KBR) has completed an independent engineering assessment of its seawater uranium extraction platform. The assessment covered the uranium extraction platform, deployment architecture, offshore operation plans, uranium recovery process, commercialization pathway, and key engineering conditions required for future large-scale deployment. The assessment reviewed SuperCritical Materials' conceptual production plan. Under this plan, the system would use approximately 10,000 metric tons of adsorbent and operate on a continuous 21-day deployment cycle, capable of supporting a uranium processing facility with an annual output of 1.85 million pounds of triuranium octoxide (U3O8)...

2026-08-27

American Fusion's Fusion Platform Patent Applications Reach 100

American Fusion announced on August 24 that the total number of patent applications it has filed around its Texatron Fusion Engine platform has reached 100, including 17 newly filed U.S. patent applications. The company stated that these applications primarily cover the structural design, fuel injection, electromagnetic configuration, and system architecture of the Texatron platform. According to the company's disclosure, the 17 newly filed applications were submitted between August 16 and 22, 2026, covering aluminum fusion confinement structures, clamshell and monobloc housings, hollow annular inner cavities, rifled inner wall geometries, electromagnetic field structures, helium-3 and deuterium...

2026-08-25

China Nuclear Power Industrial Internet Platform Optimization Project Passes Technical Acceptance

On August 18, China Nuclear Power organized the technical acceptance of the centralized R&D project "Optimization, Expansion, and Application Deepening Research of the Nuclear Power Industrial Internet Platform" in Wuhan. The expert panel reviewed the project team's report on the completion of project objectives, research content, technical indicators, and expected outcomes, examined the documentation, and after inquiry and discussion, unanimously agreed that the project has comprehensive research content, met technical indicators, achieved outstanding innovation results, demonstrated good pilot application effects, and maintained complete and standardized documentation, approving the technical acceptance. The Nuclear Power Industrial Internet Platform (DHP) serves as the solid group-level foundation for China Nuclear Power's digital development, undertaking the coordination of data element circulation across multiple bases and reactor types,...

2026-08-22

South Korea's Asan Medical Center Develops AI-Based Radiopharmaceutical Therapy Platform with U.S. Institutions

The research team at Asan Medical Center in Seoul announced on the 21st that it has recently been selected for the "2026 Korea-U.S. Innovative Outcomes R&D New Support Project" organized by the Ministry of Health and Welfare, and will collaborate with U.S. research institutions to develop an artificial intelligence-based radiopharmaceutical therapy platform aimed at exploring new treatment strategies for solid tumors that respond poorly to conventional therapies. The team is composed of professors including Myung Seung-jae from the Department of Gastroenterology, Oh Seung-jun from the Department of Nuclear Medicine, Ryu Chang-hoon from the Department of Oncology, Jung Byung-kwan from the Department of Pathology, and Son Byung-ho from the Department of Breast Surgery at Asan Medical Center. The project will combine Asan Medical Center's large-scale clinical and pathological data, Emory University's AI-based digital pathology analysis technology, and Case Western Reserve University and University Hospitals Cleveland Medical Center's pathological and clinical research capabilities.

2026-08-22